😒🚬🈁
The stock price of Second Sight Medical Products Inc (NASDAQ: EYES) is trading at over 30% pre-market. This is why it happened.
The stock price of Second Sight Medical Products Inc (NASDAQ: EYES) is trading at over 30% pre-market. This is a continuation in momentum as the company’s stock price increased 103.28% yesterday despite a broader market selloff.
Why has the company stock price increased? Investors have been responding to the company announcing that the U.S. Food and Drug Administration (FDA) has approved the Argus 2s Retinal Prosthesis System, a redesigned set of external hardware (glasses and video processing unit) initially for use in combination with previously implanted Argus II systems for the treatment of retinitis pigmentosa (RP). And the company expects that the Argus 2s will be adapted to be the external system for the next generation Orion Visual Cortical Prosthesis System currently under development.
Along with ergonomic improvements, the Argus 2s system offers significantly more processing power, potentially allowing for improved video processing.
A decision on when or if to begin production of the newly approved hardware is pending completion of Second Sight’s planned business combination with Pixium Vision, which currently is in progress. And if the business combination is completed, then the new management team will then evaluate how best to proceed with the Argus 2s Retinal Prosthesis System, as well as all other products in development.
Pre－marketでも大幅高‼️
投資の参考になりましたか？
